Bridging Analyses: The Role of Cost Per Event A...

By João L. Carapinha

March 17, 2026

This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucag...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform
South Africa Health Reform: Navigating Innovations and Challenges for 2026
National HealthTech Access: Transforming NHS Adoption and Equity
Healthcare Innovation Trends Shaping the Future: Insights from the J.P. Morga...
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Navigating Economic Resilience Through Life Sciences Investment
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays